Medicamen Biotech Ltd (MEDICAMEQ) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 770569, "name": "Medicamen Biotec", "stock_name": "Medicamen Biotec", "full_name": "Medicamen Biotech Ltd", "name_url": "stocks-analysis/medicamen-biotec", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "330.25", "chg": -17.35, "chgp": "-4.99%", "dir": -1, "prev_price": "347.60", "mcapval": "449.00 Cr", "mcap": "Micro Cap", "scripcode": 531146, "symbol": "MEDICAMEQ", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE646B01010", "curr_date": "Sep 18, 03:30 PM", "curr_time": "18:20 PM", "last_traded_at": "Sep 18, 03:30 PM IST", "bse_nse_vol": "31.32 k", "exc_status": "Active", "traded_date": "Sep 18, 2026", "traded_date_str": "2026 09 18", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-biotec-770569-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Medicamen Biotech Gains 2.09%: Downgrade and Lower Circuit Mark a Volatile Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-gains-209-downgrade-and-lower-circuit-mark-a-volatile-week-4198321", "imagepath": "", "date": "2026-09-19 15:02:48", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>15 Sep:</strong> Downgrade to Sell rating by MarketsMOJO amid technical and valuation concerns</p>\n <p><strong>16 Sep:</strong> Sharp rebound with a 7.95% gain following downgrade</p>\n <p><strong>18 Sep:</strong> Stock hits lower circuit limit, closing down 4.99%</p>\n <p><strong>18 Sep:</strong> Week closes at Rs.330.25, up 2.09% from previous Friday</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.323.50</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div>..." }, { "title": "Medicamen Biotech Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-hits-lower-circuit-amid-heavy-selling-pressure-4197102", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/MedicamenBiotec_stocks_hitting_lower_circuit_4197102.png", "date": "2026-09-18 10:00:15", "description": "At Rs 332.00, Medicamen Biotech Ltd found itself locked at its lower circuit on 18 Sep 2026, with a 5% price band limiting the day's decline. Despite sellers lining up to exit, no buyers emerged to absorb the supply, resulting in a frozen price and unfilled sell orders that highlight the stock's liquidity challenges." }, { "title": "Medicamen Biotech Downgraded to Sell Amid Technical and Valuation Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-downgraded-to-sell-amid-technical-and-valuation-concerns-4194464", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/MedicamenBiotec_mojoScore_4194464.png", "date": "2026-09-16 08:27:38", "description": "Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 15 September 2026. This decision follows a comprehensive reassessment across four critical parameters: quality, valuation, financial trend, and technicals. The downgrade reflects a combination of subdued financial performance, deteriorating technical indicators, and a shift in valuation metrics, signalling caution for investors amid challenging market conditions." }, { "title": "Medicamen Biotech Gains 19.57%: 2 Key Factors Driving the Surge", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-gains-1957-2-key-factors-driving-the-surge-4191426", "imagepath": "", "date": "2026-09-12 14:03:24", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>7 Sep:</strong> Stock opens at Rs.277.25, up 2.48% despite Sensex decline</p>\n <p><strong>9 Sep:</strong> Sharp 9.04% jump to Rs.311.35 amid valuation shift news</p>\n <p><strong>10 Sep:</strong> Valuation grade downgraded to fair; technical outlook improves</p>\n <p><strong>11 Sep:</strong> Upgrade to Hold rating announced; stock closes at Rs.323.50 (+5.37%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.270.55</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Clos..." }, { "title": "Medicamen Biotech Ltd Upgraded to Hold as Technicals Improve and Valuation Adjusts", "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-upgraded-to-hold-as-technicals-improve-and-valuation-adjusts-4189902", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/MedicamenBiotec_mojoScore_4189902.png", "date": "2026-09-11 08:07:34", "description": "Medicamen Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance and long-term growth. The upgrade, effective from 10 September 2026, is driven primarily by a shift in technical trends and a reassessment of valuation, while quality and financial trend parameters remain subdued." }, { "title": "Medicamen Biotech Ltd Valuation Shifts Signal Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-valuation-shifts-signal-changing-market-sentiment-4188419", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/MedicamenBiotec_valuationdot_4188419.png", "date": "2026-09-10 08:00:46", "description": "Medicamen Biotech Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector landscape. Despite a strong recent price rally, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered price attractiveness compared to historical and peer benchmarks." }, { "title": "Medicamen Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-4182350", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/MedicamenBiotec_mojoScore_4182350.png", "date": "2026-09-04 10:11:07", "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Medicamen Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-4166689", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/MedicamenBiotec_mojoScore_4166689.png", "date": "2026-08-24 10:11:10", "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 August 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Medicamen Biotech Gains 2.22%: 3 Key Factors Driving the Weekly Recovery", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-gains-222-3-key-factors-driving-the-weekly-recovery-4165377", "imagepath": "", "date": "2026-08-22 15:05:37", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>17 Aug:</strong> Stock hits 52-week low of Rs.214.9 amid weak financials</p>\n <p><strong>18 Aug:</strong> Further decline to fresh 52-week low of Rs.210.1; valuation metrics improve</p>\n <p><strong>20 Aug:</strong> Sharp rebound with 6.79% gain to Rs.244.70</p>\n <p><strong>21 Aug:</strong> Week closes with modest gain at Rs.246.10 (+0.57%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\">\n <div class=\"stat-label\">Week Open</div>\n <div class=\"stat-value\">Rs.240.75</div>\n </div>\n <di..." } ], "total": 6276, "sid": "770569", "stock_news_url": "https://www.marketsmojo.com/news/medicamen-biotech-770569" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "05-Sep-2026", "details": "Announcement under Regulation 30(LODR) - Newspaper Publication AGM 2026", "source": "BSE" }, { "caption": "Reg. 34 (1) Annual Report.", "datetime": "03-Sep-2026", "details": "Reg 34 (1) Annual Report", "source": "BSE" }, { "caption": "Business Responsibility and Sustainability Reporting (BRSR)", "datetime": "03-Sep-2026", "details": "Business Responsibilty and Sustainability Report - 2025-26", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Medicamen Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Sep 26", "dt": "2026-09-18", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

7 Sep: Stock opens at Rs.277.25, up 2.48% despite Sensex decline

9 Sep: Sharp 9.04% jump to Rs.311.35 amid valuation shift news

10 Sep: Valuation grade downgraded to fair; technical outlook improves

11 Sep: Upgrade to Hold rating announced; stock closes at Rs.323.50 (+5.37%)

Week Open

Rs.270.55

Week Clos...

Read full news article

Medicamen Biotech Ltd Upgraded to Hold as Technicals Improve and Valuation Adjusts

2026-09-11 08:07:34

Medicamen Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance and long-term growth. The upgrade, effective from 10 September 2026, is driven primarily by a shift in technical trends and a reassessment of valuation, while quality and financial trend parameters remain subdued.

Read full news article

Medicamen Biotech Ltd Valuation Shifts Signal Changing Market Sentiment

2026-09-10 08:00:46

Medicamen Biotech Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector landscape. Despite a strong recent price rally, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered price attractiveness compared to historical and peer benchmarks.

Read full news article

Medicamen Biotech Ltd is Rated Sell

2026-09-04 10:11:07

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Medicamen Biotech Ltd is Rated Sell

2026-08-24 10:11:10

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 August 2026, providing investors with the latest insights into the company’s performance and outlook.